Introduction

The safe administration of iodinated contrast media underpins every modern CT and interventional radiology service. Despite decades of refinement, contrast-associated acute kidney injury (CA-AKI) and hypersensitivity reactions remain the two most significant adverse events that can transform a routine diagnostic examination into a life-threatening emergency. This article synthesises the 2026 worldwide consensus — anchored by the ACR Manual on Contrast Media (2025 edition), the ESUR Guidelines v10, and KDIGO 2024 — into a single, actionable framework for radiographers, radiologists, and hospital administrators.

eGFR thresholds and renal risk stratification

The transition from serum creatinine alone to estimated glomerular filtration rate (eGFR) has fundamentally changed how radiology departments stratify renal risk before contrast administration. eGFR, calculated using the CKD-EPI or MDRD equation, adjusts creatinine for age, sex, and body surface area, providing a more physiologically accurate measure of renal reserve.¹

The ACR-NKF consensus threshold

The landmark 2020 ACR-National Kidney Foundation consensus statement, retained and reinforced in the 2025 ACR Manual, establishes a clear risk hierarchy:²

• eGFR >=30 mL/min/1.73 m2: Standard-dose iodinated contrast can be administered without routine prophylaxis. Post-procedure creatinine measurement is not required for stable patients.
• eGFR 30-44 mL/min/1.73 m2: Prophylactic intravenous isotonic saline may be considered when additional risk factors (diabetes, dehydration, heart failure, or nephrotoxic medications) are present.
• eGFR <30 mL/min/1.73 m2: This is the definitive threshold for added caution. Contrast should only be given when the diagnostic benefit clearly outweighs the risk of CA-AKI. Isotonic saline hydration is strongly recommended, and nephrology consultation should be considered.

The I-dose/eGFR ratio

Beyond absolute eGFR, the iodine dose-to-eGFR ratio (grams of iodine divided by eGFR in mL/min/1.73 m2) provides a more nuanced risk predictor. A ratio <1.42 is considered safe, whereas ratios >1.42 correlate with exponentially increasing CA-AKI risk.³ This metric is particularly valuable in obese patients or those with borderline renal function, where standard volume-based dosing may inadvertently exceed safe iodine loads.

Creatinine screening: who needs it and who does not

The 2025 ACR Manual and ESUR Guidelines v10 have both narrowed the pool of patients who require routine pre-procedure creatinine screening. Universal screening is no longer recommended in asymptomatic outpatients without risk factors.⁴

Patients who require renal function assessment

• Known chronic kidney disease (any stage)
• History of acute kidney injury within the past 6 months
• Diabetes mellitus (type 1 or type 2)
• Age >60 years
• Hypertension with end-organ damage
• Single kidney, kidney transplant, or prior nephrectomy
• Concurrent nephrotoxic medications (NSAIDs, aminoglycosides, ACE inhibitors, diuretics)
• Planned intra-arterial contrast administration (higher nephrotoxic risk than intravenous)

Post-procedure creatinine testing

Routine post-procedure creatinine measurement is no longer recommended for stable patients with normal baseline renal function. It should be reserved for:⁵

• Patients with eGFR <30 mL/min/1.73 m2 who received contrast
• Patients who developed symptoms suggestive of CA-AKI (oliguria, peripheral oedema, rising creatinine on day 2-3)
• Patients who received unusually large contrast volumes (>100 mL of 350 mgI/mL equivalent)

Society recommendations across continents

While the ACR Manual dominates North American practice, European, Asian, and Australasian societies have developed complementary frameworks that differ in nuance but converge on core principles.

All major societies now agree that the eGFR <30 threshold represents the point at which contrast administration shifts from routine to high-risk, requiring documented informed consent, hydration, and post-procedure monitoring.⁶

Saline hydration: the only proven prevention

Of all pharmacological and non-pharmacological interventions studied for CA-AKI prevention, isotonic intravenous saline hydration is the only strategy supported by consistent level-1 evidence and endorsed unanimously across all major guidelines.⁷

Standard protocol

The classic regimen is 0.9% sodium chloride at 1 mL/kg/hour for 12 hours before and 12 hours after contrast exposure. For patients unable to tolerate 24-hour hydration, a modified protocol of 3 mL/kg/hour for 1 hour pre-contrast and 1 mL/kg/hour for 6 hours post-contrast achieves comparable protection in elective settings.⁸

Oral hydration as an alternative

For outpatients with eGFR >30 and no additional risk factors, oral hydration (500 mL of water 2 hours before and 2 L over 24 hours after the examination) is an acceptable alternative to intravenous saline, provided the patient is not fluid-restricted and has normal cardiac function.⁹

Hydration in heart failure

In patients with decompensated heart failure or severe left ventricular dysfunction, aggressive saline loading risks pulmonary oedema. A reduced rate of 0.5 mL/kg/hour with continuous pulse oximetry and strict fluid balance monitoring is recommended, with nephrology and cardiology co-management.¹⁰

Bicarbonate and N-acetylcysteine: evidence revisited

The past two decades have seen a dramatic reversal in the guideline status of both sodium bicarbonate and N-acetylcysteine (NAC) for CA-AKI prevention.

Sodium bicarbonate

Early single-centre trials suggested that sodium bicarbonate (154 mEq/L infused at 3 mL/kg/hour for 1 hour pre-contrast, then 1 mL/kg/hour for 6 hours post-contrast) reduced CA-AKI by alkalinising tubular urine and scavenging free radicals. However, subsequent large RCTs and meta-analyses have produced inconsistent results.¹¹ A 2015 meta-analysis of 20 RCTs (n = 4,280) found that while bicarbonate reduced CA-AKI in low-osmolar contrast settings (OR 0.59) and emergency procedures (OR 0.16), it showed no benefit with iso-osmolar agents or elective cases.¹² The 2025 ACR Manual no longer recommends bicarbonate as routine prophylaxis.

N-acetylcysteine

NAC (600 mg orally twice daily for 24-48 hours around contrast exposure) was widely adopted in the 2000s based on small trials showing modest creatinine protection. The landmark ACT trial (2018, n = 5,178) and subsequent meta-analyses demonstrated no reduction in death, dialysis, or persistent renal dysfunction.¹³ The 2024 KDIGO Controversies Conference and 2025 ACR Manual both explicitly state that NAC should not be used as the sole or primary prophylactic strategy. It may be considered as an adjunct in high-risk patients already receiving saline, but never as a substitute for hydration.

Metformin and iodinated contrast: 2026 guidance

Metformin is not nephrotoxic, but it is renally cleared. In the setting of contrast-induced renal impairment, accumulated metformin can precipitate metformin-associated lactic acidosis (MALA), a rare but potentially fatal complication.¹⁴

Current recommendations by eGFR

• eGFR >=60 mL/min/1.73 m2: Continue metformin. No interruption required for intravenous contrast. Monitor renal function if clinically indicated.
• eGFR 45-59 mL/min/1.73 m2: Continue metformin with enhanced monitoring (renal function every 3-6 months). No interruption required for intravenous contrast.
• eGFR 30-44 mL/min/1.73 m2: Reduce metformin dose by 50%. For intravenous contrast, continuation is supported by 2025 meta-analyses showing no increased CA-AKI or acidosis risk.¹⁵ For intra-arterial contrast, discontinue 48 hours before and restart 48 hours after if renal function is stable.
• eGFR <30 mL/min/1.73 m2: Metformin is contraindicated. If contrast is absolutely necessary, discontinue metformin at the time of exposure and recheck eGFR 48 hours before restarting.

Intra-arterial versus intravenous contrast

Intra-arterial administration (e.g., coronary angiography, aortography) carries higher nephrotoxic risk than intravenous administration due to direct renal artery iodine exposure. The ACR and FDA therefore mandate metformin discontinuation for 48 hours before intra-arterial contrast in patients with eGFR <60 or any risk factor, regardless of baseline renal function.¹⁶

Premedication for hypersensitivity reactions

A documented prior moderate or severe hypersensitivity reaction to iodinated contrast is the strongest predictor of recurrence. The 2025 ACR Manual and the ACR-AAAAI consensus reaffirm that premedication reduces but does not eliminate breakthrough reactions, and a qualified physician must remain immediately available throughout every contrast examination.¹⁷

Standard elective premedication

• Prednisone 50 mg orally at 13 hours, 7 hours, and 1 hour before contrast injection, plus diphenhydramine 50 mg orally 1 hour before contrast.
• Alternative: Methylprednisolone 32 mg orally at 12 hours and 2 hours before contrast, plus diphenhydramine 50 mg 1 hour before.

Urgent / accelerated premedication

For emergent imaging where standard timing is impossible:

• IV hydrocortisone 200 mg (or methylprednisolone 40 mg) immediately, then every 4 hours until contrast is given, plus IV diphenhydramine 50 mg 1 hour before contrast.
• Even with accelerated premedication, reaction rates remain 5-10% in high-risk patients.

Shellfish and iodine allergy myths

The 2025 ACR Manual explicitly states that iodine-containing substances such as shellfish and topical povidone-iodine do not cross-react with iodinated contrast media. A history of shellfish allergy is not an indication for premedication. Only a documented prior reaction to a contrast agent itself triggers the premedication protocol.¹⁸

Low-osmolar versus iso-osmolar contrast agents

The choice of contrast agent osmolality has measurable implications for nephrotoxicity, hemodynamic tolerance, and patient comfort.

Iso-osmolar agents (290 mOsm/kg)

Iodixanol is the only iso-osmolar non-ionic dimer available. Its osmolality matches plasma, virtually eliminating osmotic diuresis, vasodilatation, and cardiac stress. Meta-analyses suggest a modest reduction in CA-AKI compared with low-osmolar monomers in patients with eGFR <30, though the absolute difference is small (approximately 2-3% absolute risk reduction).¹⁹

Low-osmolar agents (600-800 mOsm/kg)

Iohexol, iopamidol, ioversol, and iopromide are the workhorses of modern CT. They offer lower viscosity and easier injection through small-gauge catheters than iodixanol. For patients with eGFR >=30, the nephrotoxicity difference between low-osmolar and iso-osmolar agents is clinically negligible.²⁰

Pediatric considerations

Children are not small adults. Their higher cardiac output, larger blood volume relative to body mass, and immature renal tubular function demand modified dosing, enhanced monitoring, and strict attention to dehydration status.²¹

Weight-based dosing

Pediatric risk factors for CA-AKI

• Dehydration: Febrile illness, vomiting, or poor oral intake before elective CT significantly increases risk.
• Congenital heart disease: Reduced effective renal perfusion and prolonged contrast transit times.
• Nephrotoxic co-medications: Aminoglycosides, vancomycin, and NSAIDs are common in paediatric inpatients.
• Prematurity: Nephrogenesis is incomplete before 34 weeks gestation; contrast should be avoided in premature neonates unless life-saving.

Pediatric hydration

Oral hydration is preferred in children who can drink. For infants and toddlers, intravenous normal saline at maintenance rate (using the Holliday-Segar formula) for 4 hours pre- and 12 hours post-contrast is standard. Bicarbonate and NAC are not recommended in paediatric populations due to lack of efficacy data and risk of electrolyte disturbance.²²

Contrast volume reduction strategies

The single most modifiable risk factor for CA-AKI is the total iodine load. Reducing contrast volume without compromising diagnostic quality is a core safety competency.²³

High-concentration media

Using 370-400 mgI/mL formulations allows equivalent vascular enhancement at lower injected volumes. A 60 mL bolus of 400 mgI/mL delivers the same iodine mass as 69 mL of 350 mgI/mL — a 13% volume reduction.

Saline chaser and split-bolus techniques

A 40-50 mL saline chaser pushes the contrast tail into the central circulation, reducing wasted contrast in the peripheral veins. Split-bolus protocols (dividing contrast between early arterial and delayed venous phases) can reduce total volume by 30-50% in CT urography and dual-phase abdominal imaging.²⁴

Low kVp imaging

Reducing tube voltage from 120 kVp to 80-100 kVp increases iodine attenuation by 30-50% (photoelectric effect), allowing diagnostic enhancement with 30-40% less contrast. This is now standard in renal CT angiography, CTPA, and paediatric body imaging.²⁵

Patient-specific contrast formulas

Replacing fixed-volume protocols with patient-specific formulas that account for scan time, time-to-peak, and flow rate can reduce mean contrast volumes from 80 mL to 29-33 mL without loss of image quality.²⁶

Conclusion

The 2026 worldwide consensus on contrast media safety is defined by three pillars: smart screening (eGFR-based risk stratification rather than universal creatinine testing), proven prevention (isotonic saline hydration as the only intervention with consistent evidence), and patient-specific dosing (minimising iodine load through high-concentration media, low kVp, and tailored injection protocols).

Radiology departments that embed these guidelines into their RIS, injector, and QA workflows will not only reduce the incidence of CA-AKI and hypersensitivity reactions, but also streamline throughput, reduce cancellations, and demonstrate measurable quality improvement to accreditation bodies. The days of empirical contrast dosing, blanket creatinine screening, and NAC prescription are over. Evidence-based, individualised contrast safety is the new standard of care.

Register with SATMED Health to access protocol resources, consumable solutions, and AI integration pathways aligned to every component of the contrast safety workflow.